Abstract:The complexity and overall burden of Parkinson's disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.

Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson’s disease

Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson's disease

Bioinspired Metal-Organic Framework Nanozyme Reinforced with Thermosensitive Hydrogel for Regulating Inflammatory Responses in Parkinson’s Disease

Metal-Organic Framework Based Nanozyme System for NLRP3 Inflammasome-Mediated Neuroinflammatory Regulation in Parkinson's Disease

A Dual Synergetic Nanoreactor for Managing Parkinson's Disease by Regulating Inflammation and Mitigating Oxidative Damage

Recent advances of nanomaterials for intervention in Parkinson's disease in the context of anti-inflammation

Focused ultrasound-mediated cerium-based nanoreactor against Parkinson's disease via ROS regulation and microglia polarization

Nano-particle Mediated Inhibition of Parkinson’s Disease Using Computational Biology Approach

Single-atom Nanozyme Liposome-Integrated Microneedles for in Situ Drug Delivery and Anti-Inflammatory Therapy in Parkinson’s Disease

Recent Advances of Nanomaterials for Intervention in Parkinson’s Disease in the Context of Anti-Inflammation

Tri-element nanozyme PtCuSe as an ingenious cascade catalytic machine for the amelioration of Parkinson's disease-like symptoms

Single-atom nanozyme liposome-integrated microneedles for in situ drug delivery and anti-inflammatory therapy in Parkinson's disease

Nir-Ii-Activated Yolk-Shell Nanostructures As An Intelligent Platform For Parkinsonian Therapy

Tri-element Nanozyme PtCuSe As an Ingenious Cascade Catalytic Machine for the Amelioration of Parkinson’s Disease-Like Symptoms

Brain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson's disease treatment via cooperative modulation of microglia

An Antisense Oligonucleotide-Loaded Blood–Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson’s Disease

Catalytic-Enhanced Lactoferrin-Functionalized Au-Bi2 Se3 Nanodots for Parkinson's Disease Therapy Via Reactive Oxygen Attenuation and Mitochondrial Protection.

Ultrasmall Coordination Polymers for Alleviating ROS-Mediated Inflammatory and Realizing Neuroprotection Against Parkinson’s Disease

Near-infrared Enhanced Organic Se-Doped Carbon Nitride Quantum Dots Nanozymes As SOD/CAT Mimics for Anti-Parkinson Via ROS-NF-κB-NLRP3 Inflammasome Axis

Iron Chelation Nanoparticles with Delayed Saturation As an Effective Therapy for Parkinson Disease.

Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes